Extended Data Table 3 |.
Vaccine meta-analysis datasets
| Vaccine | Pathogen | Vaccine Type | Adjuvant/Vector | Timepoints used | N | GEO/ImmPort |
|---|---|---|---|---|---|---|
|
| ||||||
| BNT162b2 | SARS-CoV-2 | mRNA | mRNA-LNP | 0,1,7,21,22,28 | 31 | GSE169159 |
| TIV | Seasonal Influenza | Inactivated | None | 0,1,7 | 19 | GSE74813/SDY56 |
| VZV | Varicella zoster | Live attenuated | VZV | 0,1,7 | 31 | GSE79396/SDY984 |
| YF17D | Yellow fever | Live attenuated | YF17D | 0,1,7 | 25 | GSE13486/SDY1264 |
| rVSV-ZEBOV (high dose) | Ebola | Recombinant viral vector | VSV | 0,1,7 | 7 | GSE97590/SDY1373 |
| MRKAd5/HIV | HIV | Recombinant viral vector | Ad5 | 0,1,7 | 10 | GSE22768/SDY1291 |
| H5N1+AS03 | H5N1 Influenza | Inactivated | AS03 | 0,1,7,21,22,28 | 33 | GSE102012 |
| MPSV4 | Meningococcus | Polysaccharide | None | 0,7 | 13 | GSE52245/SDY1260 |
| MCV4 | Meningococcus | Conjugate | None | 0,7 | 17 | GSE52245/SDY1260 |